What's new

EMEA-000813-PIP01-09-M01

EMEA-000813-PIP01-09-M01

Jun 11, 2025 - 15:05
 0
EMEA-000813-PIP01-09-M01
EMEA-000813-PIP01-09-M01
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vac...

Next Article

Human medicines European public assessment report (EPAR): Dexdor, dexmedetomidin...

Related Posts

EMEA-002736-PIP02-23

EMEA-002736-PIP02-23

Jun 6, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacoplan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0099/2024

Opinion/decision on a Paediatric investigation plan (PI...

Jun 5, 2025  0

Orphan designation: S-[5-(omega-methoxypoly(oxyethylene)-2-oxopentyl)]-L-cysteinylglycyl-L-serinylglycylgylcyl-L-isoleucyl-L-lysyl-L-glutamyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-histyl-L-isoleucyl-L-valyl-L-glutaminyl-L-serinyl-L-isoleucyl-L-isoleucyl-L-asparaginyl-L-threonyl-L-serinamide, acetate salt Treatment of cutaneous T-cell lymphoma, 13/04/2021 Withdrawn

Orphan designation: S-[5-(omega-methoxypoly(oxyethylene...

Jun 10, 2025  0